2016 Annual Meeting of the American Association for the Study of Liver Diseases*

Download All
November 11-15, 2016; Boston, Massachusetts
Examine Capsule Summaries, download slides, and review analysis by expert faculty on key studies from Boston 2016.



Regimen highly effective in difficult-to-treat populations, including cirrhotics and those with genotype 3 HCV infection.

Released: November 17, 2016

For patients with GT3 HCV infection, high SVR12 rates with once-daily treatment regardless of cirrhosis, treatment experience, or treatment duration.

Released: November 22, 2016

Glecaprevir/pibrentasvir for 12 or 16 weeks proved effective in cirrhotic patients with genotype 3 HCV infection, including those with treatment experience.

Released: November 16, 2016

Baseline NS3 and NS5A RAVs did not affect achievement of SVR8 with MK-3682/grazoprevir/ruzasvir with or without RBV.

Released: November 18, 2016

High SVR12 rates with once-daily, ribavirin-free treatment in cirrhotics and those with baseline resistance associated substitutions.

Released: November 18, 2016

Glecaprevir/pibrentasvir similarly effective in HCV/HIV-coinfected patients and patients previously treated with sofosbuvir.

Released: November 18, 2016

Triple-drug regimen effective regardless of treatment experience.

Released: November 17, 2016

In this phase IIb trial, greater benefits observed in patients with greater disease activity treated with the CCR2/5 blocker.

Released: November 23, 2016

Glecaprevir/pibrentasvir was effective in both treatment-naive and treatment experienced patients with or without compensated cirrhosis.

Released: November 18, 2016

In a mixed population of cirrhotics and noncirrhotics, higher relapse rate in patients with genotype 1a HCV infection appeared to drive failure of 8-week SOF/VEL/voxilaprevir to meet criteria for noninferiority to 12-week SOF/VEL.

Released: November 18, 2016

Treatment safe and tolerable with no discontinuations for study drug-related adverse events.

Released: November 17, 2016

Significant clinical complications including death, decompensation, and liver transplantation observed with HBV reactivation in setting of HCV DAA therapy.

Released: November 16, 2016

Selonsertib improved liver stiffness in patients with NASH and F2/F3 fibrosis, but had no effect on NAFLD Activity Score.

Released: November 18, 2016
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Merck & Co., Inc.
Gilead Sciences

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings